Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2024-10-17 Earnings Release
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and begins by stating it provides the "Third Quarter 2024 update and First Half 2024 Financial Results." It contains key financial highlights (revenue, cash position) for Q3 2024 and H1 2024, along with forward-looking statements and management changes. Crucially, it contains a disclaimer stating: "**Only the figure related to the cash position and the debt of Nicox SA as of December 31, 2023, is audited; all other figures in this press release are non-audited.**" This structure—a brief announcement of period results, key metrics, and a disclaimer about auditing status—is characteristic of an Earnings Release (ER), which provides initial highlights before a more comprehensive filing (like an IR or 10-K). It is not a full Interim Report (IR) because it focuses on highlights and uses press release formatting, nor is it a Call Transcript (CT) or Investor Presentation (IP). The presence of detailed financial tables at the end confirms it contains results, but the primary format is the release itself. H1 2024
2024-10-17 English
Nicox et Soleus signent un accord de financement de 16,5 millions de dollars combinant la vente de redevances et un financement en fonds propres
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated October 14, 2024, detailing a significant financial transaction involving Nicox SA. The key elements are: 1) Sale of royalties for $15 million, 2) Equity financing (issuance of shares and warrants) for $1.5 million, and 3) Debt restructuring/repayment. This clearly falls under corporate financing and capital structure changes. The most appropriate category is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) which focuses on performance metrics, or a simple announcement of a report (RPA). It is a detailed announcement of a capital raising event.
2024-10-14 French
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "Press Release" and announces a significant financial transaction: a royalty purchase agreement and an equity financing deal between Nicox and Soleus. It details the gross proceeds, investment terms (share subscription with warrants), debt repayment, and expected cash runway. This type of announcement, detailing fundraising, capital structure changes, and material financing activities, directly aligns with the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) as it focuses on a specific financing event rather than comprehensive periodic financial statements or results. It is too detailed and specific to be a general Regulatory Filing (RNS) or a Report Publication Announcement (RPA). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-10-14 English
Nicox annonce l’approbation de ZERVIATE en Chine
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate event: the approval of ZERVIATE in China by a licensee (Ocumension Therapeutics). It details the financial implications (royalties) and market potential. This type of announcement, which is a formal, time-stamped communication about a significant business development (licensing/regulatory milestone), fits best under the general category of regulatory announcements or news releases that aren't specifically earnings, capital changes, or management changes. Since it is a press release announcing a business milestone rather than a full financial report (like 10-K or IR) or a specific regulatory filing form, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general regulatory announcement/press release, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the royalty stream, but the primary nature is an operational/regulatory update. Given the options, RNS serves as the best catch-all for significant, non-standardized corporate news releases. The document length (6689 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA).
2024-09-18 French
Nicox Announces Approval of ZERVIATE in China
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces a specific corporate event: the approval of ZERVIATE in China by Nicox's partner. It contains key financial highlights (royalty structure, potential sales figures) and is dated September 18, 2024. This format—a brief, timely announcement of a significant business development or result—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full annual report (10-K), a detailed interim report (IR), or a transcript (CT), and it focuses on the immediate financial/commercial impact of an event, 'ER' is the most appropriate classification for a major, non-periodic business update that often accompanies or precedes formal financial reporting. It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available.
2024-09-18 English
Nicox nomme Christine Placet administrateur ; Michele Garufi se retire du Conseil d’administration
Board/Management Information Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a change in the Board of Directors: the appointment of Christine Placet and the retirement of Michele Garufi. This type of announcement, detailing changes in senior management or the board, directly corresponds to the definition of Board/Management Information. Filing Type Code: MANG (Board/Management Information). The document length is substantial (7378 chars), indicating it is the primary announcement itself, not just a brief notice of publication (RPA/RNS).
2024-09-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.